Paclitaxel
- Generic Name
- Paclitaxel
- Brand Names
- Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin
- Drug Type
- Small Molecule
- Chemical Formula
- C47H51NO14
- CAS Number
- 33069-62-4
- Unique Ingredient Identifier
- P88XT4IS4D
- Background
Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.
- Indication
Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.
- Associated Conditions
- Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer
- Associated Therapies
- -
A Study of NI-1801 in Patients With Mesothelin Expressing Solid Cancers
- Conditions
- Interventions
- First Posted Date
- 2022-06-03
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- Light Chain Bioscience - Novimmune SA
- Target Recruit Count
- 40
- Registration Number
- NCT05403554
- Locations
- 🇫🇷
Gustave Roussy, Villejuif, France, France
🇫🇷Institut Curie, Paris, France
🇫🇷Hôpital Européen Georges Pompidou, Paris, France
Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) and Electrostatic PIPAC (ePIPAC) With Paclitaxel In Patients With Peritoneal Carcinomatosis
- First Posted Date
- 2022-05-27
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- National University Hospital, Singapore
- Target Recruit Count
- 36
- Registration Number
- NCT05395910
- Locations
- 🇸🇬
National University Hospital, Singapore, Singapore
Chemoradiation Plus Tislelizumab for Conversion Therapy of Locally Nonresectable ESCC
- Conditions
- Interventions
- First Posted Date
- 2022-05-27
- Last Posted Date
- 2022-05-27
- Lead Sponsor
- Jiangsu Cancer Institute & Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT05394415
- Locations
- 🇨🇳
Jiangsu Cancer Institute & Hospital, Nanjing, Jiangsu, China
A Trial of GFH018 and Toripalimab in Combination with Concurrent Chemoradiotherapy in Stage III NSCLC Chemoradiotherapy in Stage III NSCLC
- Conditions
- Interventions
- First Posted Date
- 2022-05-23
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Genfleet Therapeutics (Shanghai) Inc.
- Target Recruit Count
- 65
- Registration Number
- NCT05386888
- Locations
- 🇨🇳
West China Hospital, Sichuan University, Chengdu, Sichuan, China
Onvansertib + Paclitaxel In TNBC
- Conditions
- Hormone Receptor/Growth Factor Receptor-Negative Breast CancerHER2-negative Breast CancerHormone Receptor Negative Breast CarcinomaBreast CancerUnresectable Breast CarcinomaLocally Advanced Breast CancerMetastatic Breast CancerInvasive Breast CancerTriple Negative Breast Cancer (TNBC)Inflammatory Breast Cancer
- Interventions
- First Posted Date
- 2022-05-20
- Last Posted Date
- 2024-05-20
- Lead Sponsor
- Antonio Giordano, MD
- Target Recruit Count
- 50
- Registration Number
- NCT05383196
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconness Medical Center, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-05-19
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 540
- Registration Number
- NCT05382299
- Locations
- 🇺🇸
Florida Cancer Specialists - North Region Research Office,521 North Lecanto Highway, Lecanto, Florida, United States
🇺🇸Florida Cancer Specialists,1100 Goodlette Road, Naples, Florida, United States
🇺🇸Florida Cancer Specialists,681 4th Avenue North, Naples, Florida, United States
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-05-19
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 440
- Registration Number
- NCT05382286
- Locations
- 🇺🇸
University of Pennsylvania Abramson Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸Magee-Womens Hospital of UPMC, Pittsburgh, Pennsylvania, United States
🇺🇸Magee-Womens Hospital of UPMC,5115 Centre Avenue, Pittsburgh, Pennsylvania, United States
A Study of BGB-24714 as Monotherapy and With Combination Therapies in Participants With Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2022-05-19
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 210
- Registration Number
- NCT05381909
- Locations
- 🇦🇺
Icon Cancer Centre South Brisbane, South Brisbane, Queensland, Australia
🇦🇺Peter Maccallum Cancer Centre, Melbourne, Victoria, Australia
🇺🇸Banner Md Anderson Cancer Center, Gilbert, Arizona, United States
A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)
- Conditions
- Interventions
- First Posted Date
- 2022-05-16
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 637
- Registration Number
- NCT05374512
- Locations
- 🇬🇧
Research Site, Warwick, United Kingdom
A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer
- First Posted Date
- 2022-05-09
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 305
- Registration Number
- NCT05365581
- Locations
- 🇰🇷
Site KR82003, Seocho-gu, Seoul, Korea, Republic of
🇰🇷Site KR82005, Seodaemun-gu, Seoul, Korea, Republic of
🇰🇷Site KR82001, Guro-gu, Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.